녹십자홀딩스

005250KOSPI

61.8 / 100

Reference Date: 2026-09-09

Financial Score22.5 / 40

News Sentiment21.3 / 25

Momentum8.0 / 20

Disclosure10.0 / 15

AI Analysis: PBR is significantly undervalued vs. peers but ROE is below the industry average. Slightly down 4.8% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Samsung Biologics Holdings Co., Ltd. is a holding company established in 2001, managing 54 subsidiaries across five business segments, including pharmaceuticals, diagnostics, and healthcare services. While the holding company oversees strategic planning and portfolio management, subsidiaries handle operational activities. The company has expanded its domestic and international revenue and asset base.

Number of Employees

163people

Average Salary

78.5M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 15.004.0Point

PBR

0.26Industry Average 1.207.0Point

Half of industry avg (excellent)

ROE

-2.31Industry Average 8.000.0Point

Well below industry avg

Debt Ratio

39.54Industry Average 100.006.5Point

Half of industry avg (excellent)

Trend 2023~20255.0 / 10 points

Revenue Growth Rate

2.0 / 3

Avg ▲9.2% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲236.4% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -2.2% (improving, 3yr)

Detailed News Sentiment

4 totalPositive 4Neutral 0Negative 0Average Sentiment Score 85

Positive
지씨셀, 세포치료제 기반 '상업화 성과 확인 구간' 진입
녹십자홀딩스 자회사 지씨셀의 세포치료제 상업화 성공으로 인해 긍정적인 시장 반응 예상.
Positive
GC, 베트남 건강검진서 림프종 발견…국내 치료 연계
GC의 베트남 건강검진센터에서 림프종 발견 사례를 통해 국내 치료 연계 성공, 글로벌 네트워크 확장 기대.
Positive
디지털헬스에 지갑 연 제약사…병원 영업망 타고 매출도 ‘쑥’
녹십자홀딩스의 디지털헬스 분야 투자 확대로 매출 증가 전망이 밝아짐.

Detailed Momentum

52-week position1.0Point

Near 52w low (9%, downtrend)

Current 9,820Won52-week high 17,17052-week low 9,040

1-month return2.0Point

1m -4.75% (slight drop)

Volume trend5.0Point

Volume increasing

Detailed Disclosure

1 totalPositive 0Neutral 1Negative 0

Neutral반기보고서 (2026.06)2026-08-14